Spectral Medical (TSX: EDT) posts C$2.44m revenue as PMA submission slips to May 2026 and derivative liabilities widen the reported loss

Spectral Medical Inc. (TSX: EDT), the Toronto-based late-stage theranostic company, has reported full-year revenue of C$2.44 million for fiscal 2025, a 6.8% increase over the C$2.29 million recorded in fiscal 2024, alongside a net loss of C$47.69 million driven almost entirely by a non-cash fair-value adjustment on derivative liabilities. The company simultaneously disclosed that its Premarket Approval submission to the U.S. Food and Drug Administration for its Polymyxin B Hemoadsorption device, known commercially as Toraymyxin or PMX, has shifted from a previously stated Q1 2026 target to late April or mid-May 2026. That revised timeline reflects an FDA request to incorporate complete 12-month mortality data from the Tigris Phase 3 trial into the submission package. Spectral Medical’s EDT shares were trading near C$1.36 at the time of this report, off from a 52-week high of C$1.84 but well above the 52-week low of C$0.46, a range that broadly tracks the clinical and regulatory progress the company has made over the past 12 months.

Why did Spectral Medical’s reported loss balloon to C$47.7M when revenue only grew 6.8% in fiscal 2025?

The headline loss figure requires careful decomposition before it can be meaningfully interpreted. Of the C$47.69 million comprehensive loss for the year, C$38.02 million consists of a non-cash fair-value adjustment on derivative liabilities tied to the company’s convertible notes structure. This accounting item does not represent cash leaving the business; it reflects the mark-to-market movement in the embedded derivative instruments attached to Spectral Medical’s outstanding convertible notes. As EDT shares appreciated through the year, the theoretical cost of those conversion rights increased, producing an accounting charge that dwarfs every other line on the income statement.

Stripping that adjustment out, together with other non-cash items including C$2.12 million in share-based compensation and a C$5.39 million finance income on a promissory note, the underlying cash consumption picture is more informative. Net cash used in operating activities was C$9.52 million, compared to C$8.82 million in fiscal 2024, an increase of roughly C$0.7 million year-on-year. That modest increase in cash burn reflects a company that is spending selectively: consulting and professional fees, the single largest operating cost line at C$4.77 million, actually fell from C$4.94 million the prior year. Salaries and benefits edged up to C$4.19 million from C$4.05 million, consistent with a modestly larger team advancing regulatory filing work.

How does Spectral Medical’s gross margin performance and EAA diagnostic revenue translate into commercial readiness for PMX launch?

Revenue growth of 6.8% to C$2.44 million came alongside a meaningful improvement in gross profit margin, which expanded from C$1.47 million in fiscal 2024 to C$1.71 million in fiscal 2025. Gross margin as a proportion of revenue moved to approximately 70%, up from around 64% in the prior year, driven primarily by lower cost of goods sold. The reduction in raw materials and consumables costs from C$0.75 million to C$0.38 million reflects improved production economics in the Endotoxin Activity Assay diagnostic business, which remains the company’s sole commercial revenue source at this stage.

The EAA test, which identifies patients with elevated endotoxin levels characteristic of endotoxic septic shock, serves a dual commercial function for Spectral Medical. It generates current cash and, more importantly, positions Vantive as a diagnostics distributor with existing ICU relationships that would serve as a natural commercial conduit for PMX upon approval. Vantive’s PrisMax system, which already has a substantial installed base in U.S. intensive care units, is the designated primary device for PMX hemoperfusion treatments at commercial launch. The diagnostic pipeline and the therapeutic pipeline are therefore not independent revenue streams but integrated components of a single go-to-market architecture.

What do the Tigris trial Lancet publication and SCCM presentation mean for the FDA PMA review and commercial positioning?

The clinical story underpinning the PMA submission became substantially stronger in late 2025 and early 2026. The Tigris trial results, which were initially released in August 2025, were subsequently published in The Lancet Respiratory Medicine, one of the higher-tier journals in critical care. Publication in a peer-reviewed journal of that standing provides independent validation of the trial methodology and results, which matters to regulatory reviewers and to hospital procurement committees that will eventually decide whether to stock and use PMX.

The trial results themselves are material. Across 157 patients randomized 2:1 between PMX plus standard care and standard care alone, the Bayesian statistical model produced a 95.3% probability of benefit for 28-day all-cause mortality, exceeding the prespecified 95% threshold that constituted the primary endpoint. On the key secondary endpoint of 90-day mortality, the probability of benefit reached 99.4%. After adjusting for baseline severity differences between arms, the absolute risk reduction for mortality was 10.3 percentage points at 28 days, corresponding to a number needed to treat of approximately 9.7 patients to prevent one death. At 90 days, the absolute risk reduction widened to 15.5 percentage points, with a number needed to treat of 6.5. These are clinically consequential figures in a disease setting, endotoxic septic shock, where no approved targeted treatment currently exists in the United States.

On March 24, 2026, the Tigris results were presented in the Late-Breaking Studies Affecting Patient Outcomes session at the Society of Critical Care Medicine Annual Congress in Chicago, the most prominent academic forum for intensivists and critical care physicians in North America. Placement in a late-breaking session at SCCM is not a routine occurrence and reflects the scientific committee’s judgment that these findings carry immediate clinical relevance. The presentation audience, intensivists who manage septic shock patients daily, represents the prescriber community for PMX at commercial launch. Scientific credibility established before approval reduces the physician education burden post-launch.

Why did the FDA ask for 12-month mortality data and what does the revised PMA timeline signal about regulatory risk?

The slip from Q1 2026 to late April or mid-May 2026 for the PMA submission is the detail most likely to attract scrutiny from investors who have been calibrating expectations around an earlier filing. The company’s explanation attributes the delay to two factors: an FDA request to incorporate complete 12-month mortality follow-up data from the Tigris trial, and the completion of certain non-clinical module items, specifically human factors engineering testing.

The FDA’s interest in 12-month mortality data is analytically sensible rather than a sign of skepticism about the 28-day and 90-day results. Medical device approvals, particularly for devices used in acute life-threatening conditions, increasingly incorporate longer-term follow-up requirements. The Tigris trial’s 90-day results already showed a stronger treatment effect than the 28-day endpoint, which itself exceeded the primary endpoint threshold. Requesting 12-month data is consistent with building the most comprehensive possible evidentiary record for a device that, if approved, could be routinely used in tens of thousands of patients annually. From a regulatory strategy perspective, submitting a PMA with complete long-term data also reduces the risk of the FDA issuing an Additional Information request during review, which would cause a longer delay than the filing slip itself.

Human factors engineering testing, the other cited non-clinical item, addresses how actual users interact with the device in realistic ICU conditions. FDA guidance on medical devices has placed increasing emphasis on this area over recent years, and its inclusion as a requirement rather than an optional supplement reflects the agency’s expectation that devices used by nurses and physicians in high-stress environments must demonstrate safe usability under realistic conditions. Completing this work before filing is preferable to receiving it as a deficiency notice post-submission.

How does Spectral Medical’s balance sheet and debt structure constrain and enable the path to FDA submission and commercialization?

The balance sheet tells a story of a company that is technically insolvent in accounting terms but operationally functional in the near term. Total shareholders’ deficiency reached C$69.72 million at December 31, 2025, compared to C$27.55 million a year earlier. The primary driver is the cumulative deficit of C$188.53 million, which reflects years of pre-revenue clinical-stage expenditure. Total liabilities of C$75.82 million against total assets of C$6.10 million is the arithmetic of a company funded by convertible instruments rather than equity in the traditional sense.

The most significant liability item is the derivative liability of C$46.52 million at year-end, up from C$9.74 million at end-2024. As noted, this is a non-cash accounting construct tied to the convertible notes, not a cash obligation that must be settled imminently. The underlying notes payable balance stands at C$16.44 million, and the company also carries C$4.29 million in non-current promissory notes issued in the second half of fiscal 2025. The promissory notes, extended by Vantive as part of its commercial partnership, provide up to US$10 million in non-dilutive funding to carry Spectral Medical through to PMX commercialization.

Cash on hand at December 31, 2025 was C$4.07 million, up from C$2.99 million a year earlier, supported by C$10.80 million in net cash from financing activities. That financing inflow comprised C$9.67 million from promissory note proceeds and a further C$3.40 million in aggregate from warrant and option exercises. At the current operational burn rate of approximately C$9.5 million per year, the company does not have runway through an extended commercialization ramp without additional financing. The existence of the Vantive promissory note facility, which has not been fully drawn, provides a meaningful buffer, but management will need to address longer-term capital requirements in parallel with the PMA process.

What is the market opportunity for PMX in endotoxic septic shock and how does the Vantive partnership structure the commercialization pathway?

Approximately 5 to 7 million cases of endotoxic septic shock occur globally each year, according to clinical literature referenced in Spectral Medical’s trial publications. In the United States, no targeted therapy for this subset of sepsis patients currently holds regulatory approval. PMX would enter as the first, and potentially only, approved therapeutic hemoperfusion device for this indication, which creates a market entry dynamic that is more akin to category creation than competitive displacement.

Vantive’s role as exclusive U.S. and Canada distributor removes the direct sales build-out burden from Spectral Medical’s balance sheet. Vantive, which already operates commercial infrastructure inside U.S. intensive care units through its critical care product portfolio, brings existing customer relationships, billing capability, and device reimbursement experience that would take a small company years and substantial capital to replicate independently. The structural question for long-term investors is the revenue economics of that arrangement: Spectral Medical generates EAA diagnostic revenue and, upon PMX approval, a per-unit device margin through the Vantive distribution channel. The scale of that per-unit economics against Spectral Medical’s fixed-cost base will determine whether the company can achieve profitability within a realistic timeframe post-approval.

How does EDT’s market valuation reflect the probability-weighted regulatory outcome ahead of FDA PMA submission?

Spectral Medical’s EDT shares have traded in a 52-week range of C$0.46 to C$1.84, a range that encodes considerable uncertainty about the binary regulatory outcome. At a recent price around C$1.36 and with approximately 292.6 million shares outstanding following fiscal 2025 warrant and option exercises, the company’s market capitalization is in the range of C$400 million. Against trailing revenue of C$2.44 million, that valuation is entirely a function of PMX approval optionality, not current earnings.

The analyst consensus, where available, clusters around price targets in the range of C$2.70 to C$3.50, implying that a successful PMA submission and subsequent FDA approval could support material upward re-rating. The current market price implies investors are assigning a meaningful but not certainty-level probability to that outcome. The Lancet publication, the SCCM presentation, and the FDA’s engagement on 12-month data all incrementally increase the scientific and regulatory credibility of the submission, but they do not guarantee approval. The FDA review process after a PMA submission typically runs 180 days, though Spectral Medical holds Breakthrough Device Designation, which provides access to more intensive FDA interaction and may accelerate review timing.

For investors, the key variables to monitor are the actual PMA submission date, the completeness determination from the FDA upon receipt of the filing, and any interim communications indicating the agency’s posture toward the application. A complete and accepted filing would be a more meaningful catalyst than the submission itself, as it confirms the agency has no preliminary concerns about document completeness.

Key takeaways: What Spectral Medical’s fiscal 2025 results and PMX progression mean for the company, competitors, and the septic shock market

• Revenue grew 6.8% to C$2.44 million in fiscal 2025, with gross margin expanding to approximately 70%, driven by lower production costs in the EAA diagnostic business.
• The C$47.69 million reported net loss is dominated by a C$38.02 million non-cash fair-value adjustment on derivative liabilities; underlying operating cash burn rose only modestly to C$9.52 million from C$8.82 million.
• The FDA PMA submission for PMX has shifted from Q1 2026 to late April or mid-May 2026, driven by an FDA request for complete 12-month Tigris mortality data and the completion of human factors engineering testing.
• Tigris trial results published in The Lancet Respiratory Medicine demonstrate a 95.3% probability of 28-day mortality benefit and 99.4% at 90 days, with an absolute risk reduction of 10.3 percentage points at 28 days in a disease area with no currently approved targeted U.S. therapy.
• Presentation at the SCCM Annual Congress Late-Breaking Studies session in March 2026 advances PMX’s scientific credibility with the exact prescriber audience that would drive adoption at commercial launch.
• The Vantive promissory note facility, providing up to US$10 million in non-dilutive funding, supplies near-term capital runway, though longer-term financing requirements remain an open variable ahead of commercialization.
• Vantive’s exclusive U.S. distribution partnership, underpinned by its PrisMax installed base in ICUs, structurally removes the direct sales infrastructure burden from Spectral Medical’s balance sheet.
• With Breakthrough Device Designation secured, PMA submission imminent, and a peer-reviewed Phase 3 dataset in hand, Spectral Medical is as close to a binary regulatory event as it has been in its history; the May 2026 submission window and subsequent FDA review timeline will define the investment thesis for the next 12 to 18 months.
• No existing U.S.-approved competitor in the endotoxic septic shock targeted-therapy space means PMX, if approved, enters as a category-defining product rather than a market-share contest.
• The derivative liability accounting structure, while creating outsized reported losses, does not represent near-term cash obligations and should be assessed separately from operational performance when evaluating Spectral Medical’s financial trajectory.